RecruitingNot ApplicableNCT05562960

Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP

Sponsor

National Taiwan University Hospital

Enrollment

20 participants

Start Date

May 1, 2023

Study Type

INTERVENTIONAL

Conditions

Amyotrophic Lateral Sclerosis Plasmapheresis

Summary

Patient with amyotrophic lateral sclerosis (ALS) having anti-NRIP autoantibody showed titer-dependent detrimental Effects. Plasmapheresis might benefit this subgroup of patients via removal of anti-NRIP autoantibody

Eligibility

Min Age: 20 Years

Inclusion Criteria3

Patients with amyotrophic lateral sclerosis (ALS) at the age more than 20 years and having plasma anti-NRIP autoantibody.
Agree to receive plasmapheresis intervention.
Agree to participate in the trial and receive serial examinations and follow up.

Exclusion Criteria6

Patients without plasma anti-NRIP autoantibody.
Patients requiring permanent ventilator support for ALS progression.
Not able to receive plasmapheresis or trial-related examinations.
Under pregnancy.
Blood fibrinogen level less than 50 mg/dl.
Specific ALS subtypes, including primary lateral sclerosis, progressive muscular atrophy, flail arm syndrome, or flail leg syndrome.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.